Studies have demonstrated therapeutic benefits of PDE4D inhibitors in the treatment of Alzheimer’s disease, Huntington’s disease, schizophrenia, and depression [61]. Here, PDE4D is linked to early-onset autosomal dominant Alzheimer disease.